Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?

This mini review explores the increasing prevalence of obesity in type 1 diabetes (T1D) and the challenges patients face in achieving optimal glycemic control with current treatments. It discusses the evidence supporting the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) as potential adj...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ortal Resnick, Fernando Bril, Giovanna Beauchamp
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Endocrinology
Subjects:	obesity adiposity insulin resistance overweight weight loss
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1520313/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis
by: Raveena Kelkar, et al.
Published: (2024-09-01)

Characterization of LY3324954 a long-acting glucagon-receptor agonist
by: William Roell, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
by: Noritaka Sawada, et al.
Published: (2020-01-01)

Perioperative glucagon-like peptide-1 receptor agonists–induced gastroparesis – Is gastric ultrasound the answer?
by: Suryakumar Narayanasamy, et al.
Published: (2024-09-01)

Managing cardiovascular events, hyperglycemia, and obesity in type 2 diabetes through microRNA regulation linked to glucagon-like peptide-1 receptor agonists
by: Xiaolei Miao, et al.
Published: (2025-01-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Lack of adipocyte FAM20C improves whole body glucose homeostasis
by: Liping Deng, et al.
Published: (2024-11-01)

Effects of exogenous insulin supplementation on lipid metabolism in peripartum obese dairy cows
by: Yuanyin Guo, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Prevalence and association of non-alcoholic fatty liver disease and insulin resistance among non-diabetic obese, overweight, and metabolically obese normal-weight adult patients attending at a tertiary care hospital in Eastern India
by: Samik Pramanik, et al.
Published: (2025-02-01)

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
by: Mijin Kim, et al.
Published: (2025-01-01)

The association of dietary approaches to stop hypertension measured by the food frequency questionnaire with metabolic syndrome and some inflammatory biomarkers in adolescents with obesity: a case-control study
by: Maryam Behrooz, et al.
Published: (2025-01-01)

Obesity-induced mesenteric PVAT remodelling is sexually dimorphic, but not driven by ovarian hormones
by: Lisa Ivatt, et al.
Published: (2025-01-01)

Glucagon, rather than Glucagon-Like Peptide 1, Mediates Higher Post-Lunch Glucose Excursions during Breakfast Skipping in Asian Indian Patients with Uncontrolled Type 2 Diabetes Mellitus
by: Yash V. Chauhan, et al.
Published: (2024-12-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

A review on mechanisms of action of bioactive peptides against glucose intolerance and insulin resistance
by: Forough Jahandideh, et al.
Published: (2022-11-01)

The BET inhibitor JQ1 targets fat metabolism and counteracts obesity
by: Claudia Fornelli, et al.
Published: (2025-02-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Intermittent fasting: Effectiveness and safety. A review
by: Marina V. Altashina, et al.
Published: (2024-12-01)

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
by: Feng Sun, et al.
Published: (2015-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01)

OBESITY AS A SPECIFIC OBSTACLE SUSTAINABLE SOCIAL AND ECONOMIC DEVELOPMENT
by: S. Kuzin, et al.
Published: (2016-07-01)

Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists
by: Mayeesha Ahmed, et al.
Published: (2025-02-01)

Novel findings regarding treatment obesity and weight-related comorbidities – the systemic literature review
by: Karina Urbańska, et al.
Published: (2025-01-01)

Design, Structure–Activity Relationships, and Computational Modeling Studies of a Series of α-Helix Biased, Ultra-Short Glucagon-like Peptide-1 Receptor Agonists
by: Jonathon R. Sawyer, et al.
Published: (2024-12-01)

Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia/reperfusion in rats
by: Rulin Mi, et al.
Published: (2024-12-01)

Associations of early life per- and polyfluoroalkyl substances (PFAS) exposure with body mass index and risk of overweight or obesity at age 2–18 years: Mixture analysis in the prospective Boston Birth Cohort
by: Zeyu Li, et al.
Published: (2025-01-01)

Overweight and obesity among adolescents: health-conscious behaviours, acceptance, and the health behaviours of their parents
by: Anna Lewandowska, et al.
Published: (2025-02-01)

Editorial: Exercise, diet, cytokines and obesity
by: Junhao Huang, et al.
Published: (2025-01-01)

Association between dietary betaine intake and overweight or obesity
by: Maierheba Kuerbanjiang, et al.
Published: (2024-12-01)

Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01)

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
by: XingChun Wang, et al.
Published: (2015-01-01)

Physical behaviours during pregnancy may alter the association of maternal insulin sensitivity with neonatal adiposity: a prospective pre-birth cohort of mother-child pairs
by: Piraveena Satkunanathan, et al.
Published: (2025-01-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Children’s influence over family food purchases of ultra processed foods: interference of nutritional status
by: Tailane Scapin, et al.
Published: (2015-07-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)